AFP and cancer: Covariate adjustment of the REFLECT data strongly suggests that the original noninferiority trial likely underestimated the true effect of lenvatinib on overall survival due to imbalances in baseline prognostic covariates (in particular, AFP level) and the comparatively greater use of post-treatment anti-cancer therapies in the sorafenib arm.